Can Cannabis Help with Crohn’s Disease or Other Forms of IBD?

Cannabis may relieve some symptoms for some people with inflammatory bowel disease (IBD), but it has not been established as a treatment that controls intestinal inflammation. Feeling less pain or having a better appetite does not necessarily mean that Crohn’s disease or ulcerative colitis is in remission.

The practical distinction is between symptom management and disease control. Cannabis should not replace prescribed IBD treatment or the tests used to assess whether that treatment is working.

Why Symptoms and Inflammation Must Be Assessed Separately

Crohn’s disease and ulcerative colitis involve chronic inflammation in the digestive tract. Treatment aims to control that inflammation as well as improve symptoms. Pain and bowel symptoms can persist for reasons other than active inflammation, while inflammation can sometimes continue despite relatively few symptoms.

The American Gastroenterological Association recommends monitoring strategies that combine symptoms with objective measures in Crohn’s disease and ulcerative colitis. Depending on the situation, these may include fecal calprotectin, blood tests such as C-reactive protein, and endoscopy. Your gastroenterologist can determine which assessments are appropriate.

What the Crohn’s Disease Trials Found

An often-cited 2013 trial randomized 21 people with Crohn’s disease to smoked cannabis or placebo for eight weeks. Five of 11 cannabis participants and one of 10 placebo participants met the study’s symptom-based remission threshold. However, the difference was not statistically significant, and the trial did not achieve its primary remission endpoint. A separate clinical-response measure favored cannabis. Describing the study as proving a significantly greater chance of remission is incorrect.

A 2021 randomized trial of 56 people tested an oral CBD-rich cannabis oil that also contained THC for eight weeks. Symptom scores and quality of life improved, but endoscopic scores and inflammatory markers did not show significant improvement. This was not a trial of pure CBD, and its findings cannot be applied automatically to retail CBD products.

Ulcerative Colitis and the Latest Evidence Review

In a 2021 ulcerative-colitis trial involving 32 people, eight weeks of THC-rich smoked cannabis improved clinical symptom scores and quality of life compared with placebo. The endoscopic difference between groups was not statistically significant, and the symptom benefits were not accompanied by significant improvement in inflammation measures.

A June 2026 systematic review examined four randomized trials and four controlled observational studies of THC-containing products in IBD. The randomized trials had high risk of bias, and most evidence was low to moderate quality. Results for symptoms and quality of life were mixed; remission and endoscopic outcomes did not show meaningful advantages over control. Limited safety reporting also prevented firm reassurance about harms.

The review therefore found the evidence inconclusive. It supports caution about both claims that cannabis treats the underlying disease and claims that it reliably relieves every patient’s symptoms.

Risks That Can Complicate IBD Care

THC can impair judgment and coordination and cause anxiety or other unwanted mental effects. CBD does not produce the same high, but products containing it are not automatically free of adverse effects or medication interactions.

Smoking adds respiratory exposure. Edibles avoid smoke but can have delayed and prolonged effects, making repeat dosing before the first dose has taken effect a concern. Dependence is another consideration with ongoing use.

Cannabis can also cause recurrent severe nausea and vomiting, known as cannabinoid hyperemesis syndrome. The Crohn’s & Colitis Foundation’s complementary-medicine resource includes this among its cautions. Do not assume new vomiting is simply an IBD flare or treat it by repeatedly increasing cannabis use; seek assessment and disclose your use.

A Care Plan That Does Not Rely on Symptom Relief Alone

Tell your IBD team about the product, route, frequency, and THC/CBD amounts you use or are considering. Discuss a specific symptom goal, possible interactions, and how to monitor both benefit and adverse effects. Continue prescribed treatment and planned inflammation monitoring even if you feel better.

The Foundation’s pain-management guidance recognizes reports of symptom relief but notes the lack of evidence that medical cannabis reduces IBD inflammation. If pain or diarrhea continues despite controlled inflammation, your clinician can investigate other causes and treatment options.

New severe abdominal pain, persistent vomiting, inability to keep fluids down, or fever needs prompt medical attention. Severe symptoms may require emergency care. A temporary reduction in discomfort after cannabis should not delay assessment of a possible complication.

Access rules vary by location and product. Medical-cannabis eligibility is a legal access decision; it does not establish that cannabis will induce remission or prevent IBD complications.